Top 100 VC-Backed Startups
BIOPHARMAWIRE | RESOURCE LIBRARY | INVESTOR KITS
Top 100 VC-Backed Biotech Startups
Leading biotech startups ranked by total venture funding — lead programs, clinical stage, key investors, and therapeutic focus as of Q4 2025
Updated Q4 2025 | BioPharmaWire Editors | Sources: Pitchbook, Crunchbase, company disclosures, SEC filings
This list covers 100 of the most significant VC-backed biotech companies globally, ranked by total disclosed funding within each therapeutic category. Companies that have been acquired are included where the acquisition represents a landmark exit for the sector. Companies that have completed IPOs remain listed where they retain meaningful VC backing or were recently public. The list is not exhaustive — it reflects editorial judgement about companies that are shaping the direction of the industry.
Stage key: Commercial Phase 3 Phase 2 Phase 1 IND-enabling / Preclinical
|
# |
Company |
HQ |
Focus |
Lead Program / Asset |
Stage |
Total Raised |
Key Investors |
|
ONCOLOGY (RANKED BY TOTAL FUNDING) |
|||||||
|
1 |
Agenus |
Lexington, MA |
Immuno-oncology |
AGEN1777 (anti-TIGIT bispecific) |
Phase 2 |
$1.8B |
Gilead, Bayer, Merck |
|
2 |
Relay Therapeutics |
Cambridge, MA |
Precision oncology |
RLY-2608 (PI3Kα inhibitor) |
Phase 2 |
$1.2B |
Third Rock, GV, Samsara |
|
3 |
Merus |
Utrecht, NL |
Bispecific antibodies |
Zenocutuzumab (NRG1 fusion) |
Phase 3 |
$900M |
Incyte, Sanofi, Regeneron |
|
4 |
Immunovant |
New York, NY |
FcRn-mediated diseases |
Batoclimab (anti-FcRn) |
Phase 3 |
$850M |
Roivant Sciences, RA Capital |
|
5 |
Bolt Biotherapeutics |
Redwood City, CA |
Immune-stimulating ADCs |
BDC-2034 (ISAC) |
Phase 1/2 |
$550M |
Boxer Capital, Cormorant, Foresite |
|
6 |
EQRx |
Cambridge, MA |
Oncology / biosimilars |
Aumolertinib (3rd gen EGFR TKI) |
Commercial |
$3.5B |
General Atlantic, ARCH, OrbiMed |
|
7 |
iTeos Therapeutics |
Cambridge, MA |
Immuno-oncology |
EOS-448 (anti-TIGIT) |
Phase 2 |
$800M |
GSK partnership, RA Capital, MPM |
|
8 |
PMV Pharmaceuticals |
Cranbury, NJ |
p53 reactivation |
PC14586 (p53 Y220C) |
Phase 1/2 |
$320M |
Pfizer Ventures, RA Capital |
|
9 |
Boundless Bio |
San Diego, CA |
Extrachromosomal DNA |
BBI-355 (OGT inhibitor) |
Phase 1/2 |
$210M |
Foresite, 8VC, Omega Funds |
|
10 |
Turning Point Therapeutics (BMS) |
San Diego, CA |
Kinase oncology |
Repotrectinib (ROS1/NTRK) |
Commercial |
$1.4B (acq) |
Acquired by BMS $4.1B (2023) |
|
RARE DISEASE & GENETIC MEDICINE |
|||||||
|
11 |
Prevail Therapeutics (Lilly) |
New York, NY |
Gene therapy (neurology) |
PR001 (GBA1 Parkinson’s) |
Phase 1/2 |
$1.1B (acq) |
Acquired by Eli Lilly $1.04B (2021) |
|
12 |
Passage Bio |
Philadelphia, PA |
AAV gene therapy (CNS) |
PBFT02 (GRN frontotemporal dementia) |
Phase 1/2 |
$430M |
Foresite, OrbiMed, University of Penn |
|
13 |
Encoded Therapeutics |
South San Francisco, CA |
AAV gene therapy |
ETX101 (SCN1A Dravet syndrome) |
Phase 1/2 |
$380M |
Atlas Venture, Foresite, GV |
|
14 |
Sana Biotechnology |
Seattle, WA |
Cell engineering platform |
SC291 (CD19 AlloCAR-T) |
Phase 1 |
$1.0B |
ARCH, F-Prime, GV, Foresite |
|
15 |
Graphite Bio (Kyverna) |
South San Francisco, CA |
CRISPR HSC editing |
nula-cel (SCD) |
Phase 1/2 |
$450M |
ARCH, GV, RA Capital |
|
16 |
Prime Medicine |
Cambridge, MA |
Prime editing platform |
PM359 (CGD) |
IND-enabling |
$315M |
Newpath Partners, GV, F-Prime |
|
17 |
Metagenomi |
Emeryville, CA |
Novel gene editing nucleases |
MG010 (haemophilia B) |
IND-enabling |
$275M |
Foresite, RA Capital, Samsara |
|
18 |
Verve Therapeutics |
Cambridge, MA |
Base editing (cardio) |
VERVE-101 (PCSK9 base edit) |
Phase 1/2 |
$590M |
GV, Biomatics, Leaps by Bayer |
|
19 |
Vor Biopharma |
Cambridge, MA |
Engineered HSCs + CAR-T |
VOR33 + VCAR33 (AML) |
Phase 1/2 |
$390M |
Atlas, GV, Andreessen Horowitz |
|
20 |
Rallybio |
New Haven, CT |
Rare fetal/neonatal disease |
RLYB212 (FNAIT) |
Phase 2 |
$280M |
Foresite, RA Capital, Samsara |
|
CELL & GENE THERAPY — CRISPR AND NEXT-GEN EDITING |
|||||||
|
21 |
Caribou Biosciences |
Berkeley, CA |
CRISPR (chRDNA) alloCAR-T |
CB-010 (CD19 alloCAR-T) |
Phase 1 |
$520M |
8VC, Viking Global, Vivo Capital |
|
22 |
Umoja Biopharma |
Seattle, WA |
Lentiviral in vivo CAR-T |
VivoVec CAR-T platform |
Phase 1 |
$430M |
ARCH, Foresite, RA Capital |
|
23 |
Nkarta |
South San Francisco, CA |
Allogeneic NK cell therapy |
NKX101 (NKG2D CAR-NK) |
Phase 1/2 |
$320M |
OrbiMed, RA Capital, Sofinnova |
|
24 |
Ensoma |
Boston, MA |
In vivo HSC editing |
EN-374 (SCD) |
Preclinical |
$215M |
Atlas, GV, Andreessen Horowitz |
|
25 |
Shape Therapeutics |
Seattle, WA |
RNA editing (ADAR) |
ShapeStack platform |
Preclinical |
$165M |
RA Capital, Cormorant, Redmile |
|
AI DRUG DISCOVERY & COMPUTATIONAL BIOLOGY |
|||||||
|
26 |
Recursion Pharmaceuticals |
Salt Lake City, UT |
AI / phenomics platform |
REC-994 (cerebral cavernous malformation) |
Phase 2 |
$1.5B |
Nvidia, a16z, SoftBank |
|
27 |
Insilico Medicine |
Hong Kong / Cambridge |
AI generative chemistry |
ISM001-055 (IPF) |
Phase 2 |
$400M |
Warburg Pincus, B Capital, Sinovation |
|
28 |
Exscientia |
Oxford, UK |
AI-designed molecules |
EXS21546 (A2AR antagonist) |
Phase 1/2 |
$525M |
SoftBank, Bristol Myers Squibb, Evotec |
|
29 |
Generate Biomedicines |
Somerville, MA |
Generative biology platform |
Multiple early programs |
Preclinical |
$370M |
Flagship Pioneering, ARCH |
|
30 |
AbSci |
Vancouver, WA |
AI protein design |
ABS-101 (IL-2 variant) |
Phase 1 |
$200M |
Andreessen Horowitz, Casdin Capital |
|
31 |
BigHat Biosciences |
San Mateo, CA |
ML antibody design |
Platform / discovery stage |
Preclinical |
$195M |
DCVC Bio, Andreessen Horowitz |
|
32 |
Terray Therapeutics |
Monrovia, CA |
Ultra-high-throughput drug discovery |
Platform / multiple programs |
Preclinical |
$168M |
RA Capital, Samsara, Casdin |
|
NEUROSCIENCE & CNS |
|||||||
|
33 |
Dewpoint Therapeutics |
Cambridge, MA |
Condensate biology (CNS/oncology) |
Phase 1 programs (ALS, oncology) |
Phase 1 |
$160M |
ARCH, GV, RA Capital |
|
34 |
Passage Bio |
Philadelphia, PA |
AAV gene therapy (CNS) |
PBGM01 (GM1 gangliosidosis) |
Phase 1/2 |
$430M |
Foresite, OrbiMed, Penn |
|
35 |
Lexeo Therapeutics |
New York, NY |
AAV gene therapy (CNS/cardiac) |
LX2006 (Friedreich’s ataxia cardiac) |
Phase 1/2 |
$320M |
RA Capital, Foresite, Omega Funds |
|
36 |
Neumora Therapeutics |
South San Francisco, CA |
Precision psychiatry |
NMRA-140 (GABA-B PAM, MDD) |
Phase 2 |
$620M |
ARCH, GV, 8VC |
|
37 |
Praxis Precision Medicine |
Cambridge, MA |
Ion channel CNS |
PRAX-628 (epilepsy) |
Phase 2 |
$480M |
RA Capital, Foresite, OrbiMed |
|
38 |
MapKure (BMS spinout) |
Cambridge, MA |
RAF/MEK/ERK cascade (CNS/oncology) |
BGB-3245 (BRAF) |
Phase 1/2 |
$130M |
Boxer Capital, Cormorant |
|
39 |
Acelyrin |
Los Angeles, CA |
Immunology / CNS |
Izokibep (IL-17A inhibitor) |
Phase 2/3 |
$850M |
RA Capital, Farallon, Deerfield |
|
40 |
Vigil Neuroscience |
Cambridge, MA |
TREM2 / microglia (neurodegeneration) |
VGL101 (TREM2 agonist) |
Phase 1/2 |
$200M |
Foresite, Casdin, RA Capital |
|
IMMUNOLOGY, INFLAMMATION & AUTOIMMUNE |
|||||||
|
41 |
Alumis |
South San Francisco, CA |
TYK2 inhibition |
ESK-001 (psoriasis, RA) |
Phase 2/3 |
$450M |
RA Capital, Farallon, Foresite |
|
42 |
Cullinan Oncology / Immunology |
Cambridge, MA |
Bispecific antibodies (immuno) |
CLN-978 (CD19xCD3) |
Phase 1 |
$520M |
Foresite, Casdin, RA Capital |
|
43 |
Imvax |
Philadelphia, PA |
CNS cancer immunotherapy |
IGV-001 (GBM) |
Phase 2 |
$165M |
Multiple family offices, Penn |
|
44 |
Disc Medicine |
Watertown, MA |
Haematology (erythroid) |
Bitopertin (GlyT1, polycythemia vera) |
Phase 2 |
$270M |
RA Capital, Farallon |
|
45 |
Imago BioSciences (MSD) |
South San Francisco, CA |
LSD1 inhibition (MF) |
Bomedemstat |
Phase 2 |
$710M (acq) |
Acquired by Merck $1.35B (2023) |
|
46 |
Zenas BioPharma |
Deerfield, IL |
Autoimmune (FcRn) |
Obexelimab (CD19xFcγRIIb) |
Phase 2 |
$320M |
Deerfield, Farallon, Cormorant |
|
47 |
Kyverna Therapeutics |
Emeryville, CA |
CAR-T for autoimmune |
KYV-101 (CD19 CAR-T, autoimmune) |
Phase 1/2 |
$320M |
RA Capital, Farallon, Foresite |
|
48 |
Rapport Therapeutics |
Cambridge, MA |
GABA-A selective modulators |
RAP-219 (pain/epilepsy) |
Phase 1/2 |
$210M |
Atlas, Foresite, Casdin |
|
49 |
Mirador Therapeutics |
San Diego, CA |
Inflammation / fibrosis |
TGFβ / IL program (IBD) |
Phase 1 |
$400M |
Foresite, Atlas, RA Capital |
|
50 |
Eliem Therapeutics |
Redmond, WA |
Ion channels (CNS / pain) |
ETX-810 (NaV1.7) |
Phase 1/2 |
$190M |
RA Capital, Foresite |
|
METABOLIC, CARDIOMETABOLIC & OBESITY |
|||||||
|
51 |
Protagonist Therapeutics |
Newark, CA |
Haematology / GI peptides |
Rusfertide (polycythemia vera) |
Phase 3 |
$580M |
Foresite, RA Capital, Novo Holdings |
|
52 |
Fractyl Health |
Lexington, MA |
Metabolic disease (Revita DMR) |
Rejuva (GLP-1 gene therapy, T2D) |
Phase 1 |
$285M |
Polaris Partners, Foresite |
|
53 |
Altimmune |
Gaithersburg, MD |
GLP-1/glucagon dual agonist |
Pemvidutide (obesity, MASH) |
Phase 2 |
$240M |
Vivo Capital, Boxer Capital |
|
54 |
Metsera |
New York, NY |
Long-acting GLP-1 agonist |
MET-097i (weekly SC GLP-1) |
Phase 1 |
$290M |
Arch, GV, a16z |
|
55 |
Aardvark Therapeutics |
San Diego, CA |
Gut-restricted bitter taste receptor |
ARD-101 (obesity) |
Phase 2 |
$120M |
Novo Holdings, Pfizer Ventures |
|
RADIOLIGAND THERAPY (RLT) & NOVEL ONCOLOGY MODALITIES |
|||||||
|
56 |
Fusion Pharmaceuticals (AZ) |
Hamilton, Canada |
Actinium-225 RLT |
FPI-2265 (PSMA-225Ac) |
Phase 2 |
$890M (acq) |
Acquired by AstraZeneca $2.4B (2025) |
|
57 |
RayzeBio (BMS) |
San Diego, CA |
Actinium-225 RLT (solid tumors) |
RYZ101 (SSTR2-225Ac) |
Phase 3 |
$1.1B (acq) |
Acquired by Bristol Myers Squibb $4.1B (2025) |
|
58 |
Clarity Pharmaceuticals |
Sydney, Australia |
Copper-64/67 theranostics |
SAR-bisPSMA (prostate) |
Phase 2 |
$180M |
Longview Asset Management, Acorn Capital |
|
59 |
Lantheus Holdings |
North Billerica, MA |
Radiopharmaceuticals |
MK-6240 (tau PET tracer) |
Commercial |
$1.2B |
Public company (LNTH) |
|
60 |
Aktis Oncology |
Cambridge, MA |
Mini-protein RLT |
AK-01 (PSMA-targeted) |
Preclinical |
$165M |
Atlas, Foresite, Leaps by Bayer |
|
RNA MEDICINES — ASO, RNAI, MRNA |
|||||||
|
61 |
Arrowhead Pharmaceuticals |
Pasadena, CA |
RNAi (subcutaneous) |
ARO-APOC3 (PUNTA/hypertriglyceridemia) |
Phase 3 |
$1.3B |
Public company (ARWR) |
|
62 |
Sirnaomics |
Gaithersburg, MD |
RNAi (GalNAc + polymer) |
STP705 (TGFβ1/COX-2, CSCC) |
Phase 3 |
$140M |
OrbiMed, WuXi AppTec, Matrix Partners |
|
63 |
Arctus Biotherapeutics |
Vancouver, Canada |
LNP mRNA / gene editing |
ARCT-810 (OTC deficiency) |
Phase 2 |
$540M |
Foresite, Johnson & Johnson |
|
64 |
Generation Bio |
Cambridge, MA |
ceDNA non-viral gene therapy |
GB-601 (PKU) |
Phase 1/2 |
$310M |
ARCH, Foresite, RA Capital |
|
65 |
Larimar Therapeutics |
Bala Cynwyd, PA |
CTF (frataxin) — Friedreich’s ataxia |
Nomlabofusp (CTF) |
Phase 2 |
$210M |
RA Capital, Foresite, Invus |
|
ANTIBODY-DRUG CONJUGATES (ADCS) |
|||||||
|
66 |
Sutro Biopharma |
South San Francisco, CA |
ADC (cell-free conjugation platform) |
STRO-002 (FRα, ovarian) |
Phase 1/2 |
$480M |
Merck, Celgene/BMS, Foresite |
|
67 |
Pyxis Oncology |
New Haven, CT |
ADC / immune engager platform |
PYX-201 (fibronectin EDB ADC) |
Phase 1/2 |
$225M |
Pfizer Ventures, Foresite, Atlas |
|
68 |
Mablink Bioscience |
Lyon, France |
Hydrophilic ADC linker (PSarcosinyl) |
MBL-2 (FRα, ovarian/lung) |
Phase 1 |
$110M |
Sofinnova, Bpifrance, Omnes Capital |
|
69 |
Emergence Therapeutics |
Munich, Germany |
Biopsy-free ADC patient selection |
ECO-001 (HER2 ADC) |
Phase 1 |
$145M |
Boehringer Ingelheim Venture, HBM |
|
70 |
Elevation Oncology |
New York, NY |
HER3 ADC (NRG1 fusions) |
Seribantumab (ErbB3/HER3) |
Phase 2 |
$180M |
Foresite, Boxer, Arya Sciences |
|
PROTEIN DEGRADATION — PROTAC, MOLECULAR GLUES, CELMODS |
|||||||
|
71 |
Kymera Therapeutics |
Watertown, MA |
IRAK4 / STAT3 degradation |
KY-1005 (IRAK4, atopic dermatitis) |
Phase 2 |
$620M |
Atlas, Pfizer, Lilly, RA Capital |
|
72 |
Nurix Therapeutics |
San Francisco, CA |
E3 ligase platform (BTK degrader) |
NX-5948 (BTK degrader, B-cell) |
Phase 1/2 |
$420M |
Celgene/BMS, Leaps by Bayer, Foresite |
|
73 |
C4 Therapeutics |
Cambridge, MA |
TORPEDO degradation platform |
CFT8919 (EGFR L858R degrader) |
Phase 1/2 |
$430M |
Roche, Bayer, RA Capital |
|
74 |
Arvinas |
New Haven, CT |
PROTAC platform (AR/ER) |
Vepdegestrant (ERα PROTAC) |
Phase 3 |
$1.2B |
Pfizer partnership, RA Capital, Foresite |
|
75 |
Monte Rosa Therapeutics |
Basel, Switzerland |
Molecular glue degrader |
MRT-2359 (GSPT1, NSCLC) |
Phase 1/2 |
$430M |
MPM Capital, RA Capital, Foresite |
|
LONGEVITY, AGEING BIOLOGY & EPIGENETICS |
|||||||
|
76 |
Altos Labs |
San Francisco / Cambridge |
Cellular reprogramming (longevity) |
Platform / discovery |
Preclinical |
$3.0B |
Yuri Milner, Jeff Bezos, SoftBank |
|
77 |
Calico Life Sciences (Alphabet) |
South San Francisco, CA |
Ageing biology / longevity |
Multiple early programs |
Preclinical |
$1.5B |
Alphabet / Google, AbbVie |
|
78 |
NewLimit |
San Francisco, CA |
Epigenetic reprogramming |
Platform / discovery |
Preclinical |
$130M |
Andreessen Horowitz, Dimension Capital |
|
79 |
Retro Biosciences |
Redwood City, CA |
Longevity (autophagy, plasma) |
Multiple platforms |
Preclinical |
$180M |
Sam Altman (personal), Durable Capital |
|
80 |
Unity Biotechnology |
Brisbane, CA |
Senolytic therapies |
UBX1325 (CDK4/6i, diabetic macular oedema) |
Phase 2 |
$220M |
ARCH, Venrock, Foresite |
|
MICROBIOME, SYNTHETIC BIOLOGY & EMERGING PLATFORMS |
|||||||
|
81 |
Seres Therapeutics |
Cambridge, MA |
Microbiome therapeutics (LBP) |
SER-109 (Vowst, C. diff) |
Commercial |
$650M |
Nestlé Health Science, Flagship |
|
82 |
Vedanta Biosciences |
Cambridge, MA |
Defined bacterial consortia |
VE303 (C. diff prevention) |
Phase 3 |
$250M |
Flagship, Johnson & Johnson |
|
83 |
Ginkgo Bioworks |
Boston, MA |
Synthetic biology platform |
Cell programming platform (multiple) |
Platform |
$1.7B |
General Atlantic, Viking Global, T. Rowe |
|
84 |
Absci |
Vancouver, WA |
AI protein / antibody design |
ABS-101 (IL-2 orthogonal) |
Phase 1 |
$200M |
Andreessen Horowitz, Casdin |
|
85 |
Tessera Therapeutics |
Somerville, MA |
Gene writing (mobile genetic elements) |
Platform / early programs |
Preclinical |
$230M |
Flagship, RA Capital, GV |
|
AUSTRALIAN & ASIA-PACIFIC NOTABLE COMPANIES |
|||||||
|
86 |
Clarity Pharmaceuticals |
Sydney, Australia |
Copper theranostics (RLT) |
SAR-bisPSMA |
Phase 2 |
$180M |
Longview, Acorn Capital |
|
87 |
Paracrine Therapeutics |
Melbourne, Australia |
Exosome-based delivery |
PAR-101 (cardiac) |
Preclinical |
$45M |
Brandon Capital, Uniseed |
|
88 |
Noxopharm |
Sydney, Australia |
Tumour microenvironment |
Veyonda (IDO1/STING, prostate) |
Phase 2 |
$60M |
ASX-listed (NOX) |
|
89 |
Synpromics (ImmVira) |
Edinburgh, UK / HK |
Synthetic promoter gene regulation |
Platform / oncology programs |
Preclinical |
$90M |
Syncona, Novo Seeds |
|
90 |
Hinge Health |
San Francisco, CA |
Digital MSK therapeutics |
Digital physical therapy platform |
Commercial |
$1.0B |
Tiger Global, Coatue, Bessemer |
|
EMERGING PLATFORMS & CROSS-MODALITY COMPANIES |
|||||||
|
91 |
Neumora Therapeutics |
South San Francisco, CA |
Precision psychiatry |
NMRA-140 (GABA-B, MDD) |
Phase 2 |
$620M |
ARCH, GV, 8VC |
|
92 |
Terremoto Biosciences |
South San Francisco, CA |
Receptor pharmacology (GPCR) |
TRB-001 (delta-OR, pain) |
Preclinical |
$95M |
Atlas, ARCH, Polaris |
|
93 |
Sonata Therapeutics |
Cambridge, MA |
Chromatin remodelling (cancer) |
Platform / SWI-SNF pathway |
Preclinical |
$165M |
Atlas, GV, RA Capital |
|
94 |
Ajax Therapeutics |
New York, NY |
JAK2/CALR oncology |
AJ1-11095 (JAK2, MPN) |
Phase 1 |
$145M |
Atlas, Omega Funds |
|
95 |
Limelight Bio |
Cambridge, MA |
Selective payload delivery (LNP) |
Tissue-selective LNP platform |
Preclinical |
$72M |
GV, RA Capital, Atlas |
|
96 |
Inzen Therapeutics |
San Francisco, CA |
Ferroptosis biology |
Platform / oncology |
Preclinical |
$55M |
New Enterprise Associates, Andreessen |
|
97 |
Tango Therapeutics |
Cambridge, MA |
Synthetic lethality (MTAP del) |
TNG908 (PRMT5 inhibitor) |
Phase 2 |
$430M |
Boxer, Foresite, RA Capital |
|
98 |
Phenex Pharmaceuticals |
Heidelberg, Germany |
FXR / nuclear receptor |
PX20606 (cholestasis, NASH) |
Phase 2 |
$160M |
Boehringer Ingelheim, MSD |
|
99 |
Prelude Therapeutics |
Wilmington, DE |
CDK9 inhibition |
PRT2527 (CDK9, haematologic) |
Phase 1/2 |
$175M |
Boxer, Foresite, Omega Funds |
|
100 |
Imara (merged: Enliven) |
Sunnyvale, CA |
BCR-ABL1 (CML) |
ELVN-001 (asciminib-resistant CML) |
Phase 1/2 |
$280M |
Foresite, RA Capital, Cormorant |
What This List Tells Us About the State of Biotech VC in 2025
Oncology Still Dominates but the Lead Is Narrowing
Oncology remains the largest category by deal count and total funding, but its share of total VC deployment has narrowed from roughly 40% of all biotech deals in 2020-2021 to approximately 30% in 2024-2025. The beneficiaries are rare disease / genetic medicine, metabolic disease (driven by GLP-1 adjacency), and immunology / autoimmune. Cell and gene therapy, after a significant pullback in 2022-2023, is recovering with more selective capital deployment focused on programs with clinical proof-of-concept.
Platform vs Asset: The Tension Continues
A significant proportion of the highest-funded companies on this list are platform companies — Recursion, Altos Labs, Ginkgo Bioworks, Generate Biomedicines — that have raised enormous amounts of capital on the basis of technology and potential rather than clinical data. The market in 2024-2025 has grown more sceptical of pure platform valuations without clinical-stage programs. Companies that raised $300M+ at pre-clinical stage in 2021-2022 are facing a harder environment for Series B/C raises if their platforms have not yet produced IND-stage programs with compelling data.
The AI Drug Discovery Cohort Faces Its First Real Test
The companies in the AI drug discovery category — Recursion, Insilico, Exscientia, Generate Biomedicines, and others — are entering their most consequential period. Phase 1 and Phase 2 readouts for AI-designed compounds over the next 24 months will determine whether the category premium in valuations is justified. Early indicators are mixed: Insilico’s ISM001 (IPF) has shown Phase 2 activity; Exscientia’s EXS21546 showed Phase 1 safety signals that required redesign. The sector is watching carefully.
Geography: Boston and the Bay Area Still Dominant, But Not Exclusively
The top 100 are concentrated in Boston/Cambridge and the San Francisco Bay Area, consistent with historical patterns. But the presence of companies from Basel (Monte Rosa), Oxford (Exscientia), Sydney (Clarity), Edmonton (Fusion), and Hong Kong/Cambridge (Insilico) reflects the genuine internationalisation of biotech VC. The UK, Australian, and Canadian clusters in particular are producing more globally competitive companies than at any point in the past decade, aided by improving local VC ecosystems and supportive government R&D incentive structures.
Key Investors Appearing Most Frequently
RA Capital Management, Foresite Capital, Atlas Venture, GV (Google Ventures), ARCH Venture Partners, Boxer Capital, and Cormorant Asset Management appear as lead or co-investors across the broadest range of companies on this list. These firms have built portfolios that function as sector reference points — when they lead a round, it signals scientific credibility to co-investors and the market. The concentration of VC power in a small number of specialist life sciences investors is higher today than at any previous point, which has implications for founders: getting a term sheet from one of these firms is both a valuation premium signal and a de facto fundraising advantage in future rounds.
This list is an editorial product of BioPharmaWire based on publicly available funding data, company disclosures, and SEC filings as of Q4 2025. Total raised figures reflect disclosed funding rounds and may not capture undisclosed investments, debt facilities, or government grants. Clinical stage information is based on the most recently disclosed status. This document does not constitute investment advice. Inclusion on this list does not represent an endorsement of any company or investment.